Specifically, the recommendation is for adult patients who have had sorafenib – the standard initial treatment for advanced disease – only if they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group performance status of zero or one.
NICE’s decision is based on positive results from the global placebo-controlled CELESTIAL phase 3 pivotal trial in patients in the second or third line after treatment with sorafenib…